drugset
drugset / Trial / NCT05005468

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

NCT05005468 ↗

Phase 2 Unknown 61 enrolled Shanghai Chest Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase II, open-label, multi-cohort study, aiming to investigate safety and efficacy of Camrelizumab combined with famitinib for adjuvant treatment of stage II-IIIA non-small cell lung cancer with high-risk for relapse and no driver gene mutation.

Timeline

Start
2021-09
Primary completion
2023-08
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody — Intravenous
Subject Famitinib Small molecule — Oral

Indications

non-small cell lung carcinoma